Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma. 1990

M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
Department of Public Health, Sapporo Medical College, Hokkaido.

Employing 421 urine samples taken randomly from normal infants and 294 samples from infants with neuroblastoma, we investigated the application of values of vanillylmandelic acid (VMA), homovanillic acid (HVA) and square root of VMA2 + HVA2 to discriminate between patients and normal infants. The establishment of an HVA cut-off level is virtually impossible because of its low sensitivity. In contrast, VMA sensitivity is high, and that of square root of VMA2 + HVA2 is very similar to that of VMA although it includes HVA. Although VMA appears to be able to discriminate well, discrimination employing VMA alone would be dangerous because cases with normal VMA and abnormal HVA would be missed, especially in the first screening for which a mechanical discrimination is performed. Overlooking such cases can be avoided by the adoption of the function square root of VMA2 + HVA2. The present study suggests that the combined use of variables can be more effective than using them separately.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014642 Vanilmandelic Acid A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE. Methoxyhydroxymandelic Acid,4-Hydroxy-3-Methoxymandelic Acid,Vanillylmandelic Acid,4 Hydroxy 3 Methoxymandelic Acid,Acid, 4-Hydroxy-3-Methoxymandelic,Acid, Methoxyhydroxymandelic,Acid, Vanillylmandelic,Acid, Vanilmandelic

Related Publications

M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
January 1989, Medical and pediatric oncology,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
October 1986, The Tohoku journal of experimental medicine,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
November 1988, Journal of chromatography,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
November 1987, Clinical chemistry,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
February 1987, Pediatrics,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
June 2014, Clinical biochemistry,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
January 2022, Methods in molecular biology (Clifton, N.J.),
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
May 1997, Journal of mass spectrometry : JMS,
M Nishi, and H Miyake, and T Takeda, and N Takasugi, and J Hanai, and T Kawai
December 1981, Clinical chemistry,
Copied contents to your clipboard!